CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
LDX Treatmentdrug
Likely dose
LDX Treatment 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01070394
NCT01070394Phase 4Completed
CompareCT.gov

Evaluation of Pharmacokinetics and Profile of Clinical Response of Subacute Lisdexamfetamine Dimesylate (Vyvanse) Treatment vs. Clinical Response to Subacute Immediate Release Mixed Amphetamine Salt Therapy in Adult ADHD

NYU Langone Health·interventional·Posted Feb 18, 2010·Updated Apr 3, 2018

In Brief

A Phase 4 clinical trial evaluating LDX Treatment for Attention Deficit Hyperactivity Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effectiveness and length of effect of Vyvanse on lessening Attention-Deficit/Hyperactivity Disorder symptoms in adults. The study will also investigate the safety and tolerability of Vyvanse in adults with ADHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
CollaboratorsShire

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.4 years ago

Interventions

LDX Treatmentdrug

30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.